No Data
Express News | The National Medical Products Administration has approved enzalutamide for the treatment of new indications for metastatic hormone-sensitive prostate cancer.
We Think Shareholders May Want To Consider A Review Of Encore Capital Group, Inc.'s (NASDAQ:ECPG) CEO Compensation Package
Express News | Wanxun Automatic Control: An Kexin signed a strategic cooperation agreement with the Hefei Institute of Public Safety of Tsinghua University
Encore Capital Group Prices Upsized $500 Million Senior Notes Offering
Encore Capital Group (ECPG) said late Monday it priced a private offering of $500 million of 8.5% senior secured notes due 2030 at an issue price of 100%, with the offering upsized from $400 million.
Encore Capital Group, Inc. Announces Pricing of Upsized Senior Secured Notes Offering
SAN DIEGO, May 13, 2024 (GLOBE NEWSWIRE) -- Encore Capital Group, Inc. (NASDAQ:ECPG) (the "Company") today announced the pricing of its offering of $500.0 million aggregate principal amount of 8.500% senior secured
Encore Capital to Offer $400M Senior Secured Notes in Private Offering